Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel compared with carboplatin and paclitaxel in primary advanced or recurrent endometrial cancer: a systematic review and meta-analysis of randomized clinical trials

Fig. 5

A. Critical appraisal of RCTs according to the Cochrane Collaboration’s tool for assessing risk of bias in randomized trials. B. Funnel plot analysis of the progression-free survival of patients with dMMR (mismatch repair–deficient) endometrial cancer shows no evidence of publication bias

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us